Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets [Yahoo! Finance]
Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
Arcturus Therapeutics (NASDAQ:ARCT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Arcturus Therapeutics (NASDAQ:ARCT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]